
Novo Nordisk Expands Focus to Longevity and Aesthetics, Shares Dip
Novo Nordisk’s stock slid about 3.2% after CEO Mike Doustdar signaled a broader strategy beyond obesity and diabetes, aiming to explore longevity research and aesthetic medicine uses for GLP-1 drugs like semaglutide. While Novo presented aging-clock data suggesting organ-age reductions in the heart and kidneys, these findings aren’t proof of slowed aging. The shift comes as investors weigh the risks of heavy reliance on weight‑loss revenue amid competition from Lilly’s new therapies, with indications of a broader strategic reset into skincare and appearance-related indications.













